Uluslar arası Yayınlanan Makaleler                              

  1. N. Tözün, K. Berkman, E. Tankurt, C. Kalaycı, O. Özdoğan, S. Akan, Y. Taga. Effect of Diltiazem on renal function in patients with liver cirrhosis. İnternational Journal of Clinical Pharmacology, Therapy and Toxicology, Vol.29, No.5, 198-203, 1991.
  2. O.Özdoğan, A.J.A Saadalla, G. Emirönal, B.Ç. Yeğen, N.B Ulusoy. Effect of intraluminal   temperature  on human oesophageal motor function. Clinical Physiology 18, 6, 504509, 1998.
  3. Uyar A, İmeryüz N, Direskeneli GS, Çeken HA, Özdoğan O, Özgür Ş, Tözün N. The distribution of HLA-DRB allele in ulcerative colitis patients in Turkey. European Journal of Immunogenetics vol 25, 293-296, 1998.
  4. O. Özdoğan, C. Kalaycı. GI training and practice in Turkey. International Journal of  Gastroenterology vol 3, no 2, 17-19, 1998. (SCI’da yer almıyor)
  5. Osman Özdoğan M.D, M. Zafer Gören M.D PhD, Siret Ratip MB BS, M.D, Adnan Giral M.D, Haidi Moini PhD , Firuze Enç, Serpil Birsel PhD, Kemal Berkman MD, Nurdan Tözün MD. Role of endothelin-1 in a cirrhotic rat model with endotoxin induced acute renal failure. Hepatology Research 24, 114-124, 2002.
  6. Ozdoğan O, Ratip S, Ahdab YA, Dane F, Ahdab HA, Imeryüz N, Tözün N.Causes and risk factors for liver injury following bone marrow tansplantation. Journal of Clinical Gastroenterology, 36(5), 421-426, 2003.
  7. O. Tarcin , K Avşar , L Demirtürk, M Gültepe, BK Oktar, O.Özdoğan, Ö.Tarçın, H.Baloğlu, A K Gürbüz. In vivo efficiency of pentoxyfyllline and Interferon -Alfa on hepatic fibrosis in biliarry obstructed rats: Assesment by tissue collagen and prolidase activity. Journal of Gastroenterology and Hepatology, 18, 437-44, 2003.
  8. Tahan V, Yıldırım B, Ture F, Giral A, Özdoğan O, İmeryüz N, Avşar E, Mert A, Şentürk H, Kalaycı C, Tözün N. Anti-HCV seroprevalence in chronic HCV patients’ children in Turkey. Journal of Clinical Gastroenterology, 2003, 36 (5), 421-426.
  9. Tahan V, Özdoğan O, Tözün N. Epidemiology of viral hepatitis in the Mediterranean Basin. Annales Academia Medicae Bialostocensis, 2003, vol 48, 11-17.
  10. Adnan Giral, Osman Özdoğan, Çiğdem A. Çelikel, Nurdan Tözün, Nefise B. Ulusoy, Cem Kalaycı. The effect of helıcobacter pylorı eradıcatıon on antı-thrombotıc dose aspırın ınduced gastroduodenal mucosal ınjury. Journal of Gastroenterology and Hepatology, 2004, 19 (7),773-777 .
  11. Tea Restuccia, Rolando Ortega, Monica Guevara, Pere Ginès, Carlo Alessandria, Osman Ozdogan, Miquel Navasa, Antoni Rimola, Juan Carlos Garcia-Valdecasas, Vicente Arroyo and Juan Rodés. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. Journal of Hepatology, Vol. 40 (1) 2004, 140-146.
  12. Tahan V, Yildirim B, Ture F, Giral A, Ozdogan O, Imeryuz N, Avsar E, Mert A, Senturk H, Kalayci C, Tozun N. Anti-HCV seroprevalence in chronic HCV patients’ children in Turkey. J Clin Gastroenterol. 2004 Jan;38(1):90-1.
  13. Veysel Tahan, Resat Ozaras, Nadır Lacevıc, Ercan Ozden, Mucahıt Yemısen, Osman Ozdogan, Alı Mert, Fehmı Tabak, Erol Avsar, Cıgdem Ataızı Celıkel, Gulsen Ozbay, Cem Kalaycı, Hakan Senturk, Nurdan Tozun. Prevalence of Hepatic Granulomas in Chronic Hepatitis B. Digestive Diseases and Sciences, Vol. 49, No. 10 (October 2004), pp. 1575–1577.
  14. Ozdogan OC. Measurement of hepatic venous pressure gradient in patients with active variceal bleeding. Hepatology. 2005 Feb;41(2):406-7; author reply 407.
  15. Alessandria C, Ozdogan O, Guevara M, Restuccia T, Jiménez W, Arroyo V, Rodés J, Ginès P. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology. 2005 Jun;41(6):1282-9 (İki yazar eşit sorumludur).
  16. Güney Duman D, Tüney D, Bilsel S, Benli F, Karan S, Avsar E, Ozdogan O, Tözün N. Octreotide in liver cirrhosis: a salvage for variceal bleeding can be a gunshot for kidneys. Liver Int. 2005 Jun;25(3):527-35.
  17. Giral A, Celikel CA, Ozdogan O, Tözün N, Ulusoy NB, Kalayci C. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. J Gastroenterol Hepatol. 2005 Dec;20(12):1886-91
  18. Ozdemir FT, Duman D, Ertem D, Avşar E, Eren F, Ozdoğan O, Kalayci C, Aslan N, Bozdayi AM, Tözün N. Determination of hepatitis B genotypes in patients with chronic hepatitis B virus infection in Turkey. Turk J Gastroenterol. 2005 Dec;16(4):183-7.
  19. Ozdogan O, Tahan V, Cincin A, Imeryuz N, Tozun N. Acute pancreatitis associated with the use of peginterferon. Pancreas. 2007 May;34(4):485-7.
  20. Atug O, Hamzaoglu H, Tahan V, Alican I, Kurtkaya O, Elbuken E, Ozdogan O, Tozun N. Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis. Dig Dis Sci. 2008 Feb;53(2):481-5. Epub 2007 Oct 13.
  21. Ozdogan O, Atalay H, Cimsit C, Tahan V, Tokay S, Giral A, Imeryuz N, Baltacioglu F, Tuney D, Erzen C, Tozun N. Role of echo Doppler ultrasonography in the evaluation of postprandial hyperemia in cirrhotic patients. World J Gastroenterol. 2008 Jan 14;14(2):260-4.
  22. Yilmaz Y, Ozdogan O. Liver disease as a risk factor for cognitive decline and dementia: an under-recognized issue. Hepatology. 2009 Feb;49(2):698; author reply 698
  23. Tahan V, Atug O, Akin H, Eren F, Tahan G, Tarcin O, Uzun H, Ozdogan O, Tarcin O, Imeryuz N, Ozguner F, Celikel C, Avsar E, Tozun N. Melatonin ameliorates methionine- and choline-deficient diet-induced nonalcoholic steatohepatitis in rats. J Pineal Res. 2009 May;46(4):401-7.
  24. Tiftikci A, Atug O, Yilmaz Y, Eren F, Ozdemir FT, Yapali S, Ozdogan O, Celikel CA, Imeryuz N, Tozun N. Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. Arch Med Res. 2009 May;40(4):294-8.
  25. Yilmaz Y, Atug O, Yonal O, Duman D, Ozdogan O, Imeryuz N, Kalayci C. Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease. Med Sci Monit. 2009 Apr;15(4):HY1-5.
  26. Yusuf Yilmaz, Alla Eldeen Kedrah, Osman Ozdogan. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009 September 21; 15(35): 4387-4391
  27. Yilmaz Y, Alahdab YO, Ozdogan O, Dolar E. Non-alcoholic fatty liver disease and microalbuminuria in non-diabetic patients: role of insulin resistance. Intern Med J. 2009 Oct;39(10):709-10. PubMed PMID: 19849765.
  28. Yilmaz Y, Alahdab YO, Yonal O, Kurt R, Kedrah AE, Celikel CA, Ozdogan O, Duman D, Imeryuz N, Avsar E, Kalayci C. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism. 2010 Jan 21. [Epub ahead of print] PubMed PMID: 20096896.
  29. 2: Yilmaz Y, Kurt R, Yonal O, Polat N, Celikel CA, Gurdal A, Oflaz H, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis. Atherosclerosis. 2010 Feb 7. [Epub ahead of print] PubMed PMID: 20181335.
  30. Ozdemir FT, Tiftikci A, Sancak S, Eren F, Tahan V, Akın H, Gündüz F, Kedrah AE, Ustündağ Y, Avşar E, Tözün N, Ozdoğan O. The Prevalence of the Mutation in Codon 249 of the P53 Gene in Patients with Hepatocellular Carcinoma (HCC) in Turkey. J Gastrointest Cancer. 2010 Mar 20. [Epub ahead of print] PubMed PMID: 20306157.
  31. Yilmaz Y, Yonal O, Kurt R, Oral AY, Eren F, Ozdogan O, Ari F, Celikel CA,Korkmaz S, Ulukaya E, Imeryuz N, Kalayci C, Avsar E. Serum levels ofosteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scand J Clin Lab Invest. 2010 Dec;70(8):541-6. doi: 10.3109/00365513.2010.524933. Epub 2010 Oct 14. PubMed PMID: 20942739.
  32. Tahan G, Eren F, Tarçin O, Akin H, Tahan V, Şahın H, Özdoğan O, İmeryüz N, Çelıkel Ç, Avşar E, Tözün N. Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats. Turk J Gastroenterol. 2010 Sep;21(3):287-92. PubMed PMID: 20931434.
  33. Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY, Celikel CA, Korkmaz S, Ulukaya E, Ozdogan O, Imeryuz N, Avsar E, Kalayci C. Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem. 2010 Nov;47(Pt 6):549-53. doi: 10.1258/acb.2010.010169. Epub 2010 Oct 6. PubMed PMID: 20926473
  34. Eren F, Yilmaz Y, Kose S, Ozdemir FT, Yonal O, Kurt R, Ozdogan O, Avsar E. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B. Clin Chim Acta. 2010 Dec 14;411(23-24):2029-32. doi: 10.1016/j.cca.2010.08.035. Epub 2010 Aug 31. PubMed PMID: 20807521.
  35. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010 Oct;40(10):887-92. doi: 10.1111/j.1365-2362.2010.02338.x. Epub 2010 Aug 19. PubMed PMID: 20624171.
  36. Aktas B, Yilmaz Y, Eren F, Yonal O, Kurt R, Alahdab YO, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism. 2011 Apr;60(4):544-9. doi: 10.1016/ j.metabol.2010.05.008. Epub 2010 Jun 26. PubMed PMID: 20580037.
  37. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, Celikel CA, Imeryuz N, Kalayci C, Avsar E. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol. 2011 Jan;46(1):91-7. doi: 10.3109/00365521.2010.516452. Epub 2010 Sep 1. PubMed PMID: 20809771.
  38. Yilmaz Y, Yonal O, Eren F, Kurt R, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E. Serum zinc-α2-glycoprotein concentrations in patients with non-alcoholic fatty liver disease. Clin Chem Lab Med. 2011 Jan;49(1):93-7. doi:
  39. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Ozdogan O, Celikel CA, Ulukaya E, Imeryuz N, Kalayci C, Avsar E. Circulating levels of vascular endothelial growth factor A and its soluble receptor in patients with biopsy-proven nonalcoholic fatty liver disease. Arch Med Res. 2011 Jan;42(1):38-43. doi: 10.1016/j.arcmed.2010.12.001. PubMed PMID: 21376261.
  40. Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic  liver disease. Hepat Mon. 2011 Feb;11(2):103-6. PubMed PMID: 22087126; PubMed Central PMCID: PMC3206675.
  41. Yegin EG, Siykhymbayev A, Eren F, Bekiroglu N, Ozdogan OC. Prognostic implication of serum vascular endothelial growth factor in advanced hepatocellular carcinoma staging. Ann Hepatol. 2013 Nov-Dec;12(6):915-25. PubMed  PMID: 24114822.
  42. Dökmeci A, Ustündağ Y, Hulagu S, Tuncer I, Akdoğan M, Demirsoy H, Köklü S, Güzelbulut F, Doğan I, Demir A, Akarsu M, Yüceyar H, Ozdoğan OC, Ozdener F, Erdoğan S. The association between insulin resistance and hepatic fibrosis in patients with chronic hepatitis C: An observational, multicenter study in Turkey. Turk J Gastroenterol. 2014 Oct;25(5):546-52. doi: 10.5152/tjg.2014.7829. PubMed PMID: 25417617.
  43. Yegin EG, Eryuksel E, Giral A, Ceyhan B, Ozdogan OC. A case of dilemma in decision making of drug-induced acute pancreatitis. J Dig Dis. 2014 Oct 6. doi: 10.1111/1751-2980.12200. [Epub ahead of print] PubMed PMID: 25283755.
  44. Yegin EG, Ozdogan OC. Partial virological response to three different nucleotide analogues in naive patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int. 2014 Dec;13(6):602-11. PubMed PMID: 25475862
  45. Özdoğan OC. Covering the Cover. Turk J Gastroenterol. 2016 Sep;27(5):405-407. doi: 10.5152/tjg.2016.1600002. PubMed PMID: 27782886.
  46. Özdoğan OC. Empirical antibiotic treatment of nosocomial spontaneous bacterialperitonitis: Should we start direct broader-spectrum antibiotics or not? Turk JGastroenterol. 2016 May;27(3):294-5. doi: 10.5152/tjg.2016.160001. PubMed PMID:27210790.
  47. Toptas T, Ilhan B, Bilgin H, Dincses E, Ozdogan O, Kaygusuz-Atagunduz I,Odabasi Z, Korten V, Firatli-Tuglular T. Miliary Tuberculosis Induced Acute LiverFailure. Case Rep Infect Dis. 2015;2015:759341. doi: 10.1155/2015/759341. PubMed PMID: 26435862; PubMed Central PMCID: PMC4575992.
  48. Cinar S, Ozdogan OC, Alahdab Y. Impact of Education Provided by Nurses onQuality of Life, Anxiety, and Depression in Patients Receiving Hepatitis C Virus Therapy. Gastroenterol Nurs. 2015 Sep-Oct;38(5):343-7. doi:0.1097/SGA.0000000000000130. PubMed PMID: 26166422.
  49. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015Nov;21(11):1020-6. doi: 10.1016/j.cmi.2015.06.028. PubMed PMID: 26163105.
  50. Gonen C, Gunduz F, Doganay L, Enc FY, Yegin EG, Ahishali E, Erdem E, Sokmen M,Tuncer I, Ozdogan O. High treatment modification rates with lamivudine therapy inHBV-infected patients with low baseline viremia and early virological response: Amulticenter study. J Dig Dis. 2015 May;16(5):286-92. doi:10.1111/1751-2980.12237. PubMed PMID: 25708813.
  51. Yegin EG, Yegin K, Karatay E, Kombak EF, Tuney D, Ataizi-Celikel C, OzdoganOC. Quantitative assessment of liver fibrosis by digital image analysis:Relationship to Ishak staging and elasticity by shear-wave elastography. J DigDis. 2015 Apr;16(4):217-27. doi: 10.1111/1751-2980.12231. PubMed PMID: 25620218.
  52. Ender Gunes YEGIN1, MD; Korkut YEGIN,  Osman Cavit OZDOGAN. DIGITAL IMAGE ANALYSIS IN LIVER FIBROSIS: BASICREQUIREMENTS AND CLINICAL IMPLEMENTATION BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2016VOL. 30, NO. 4, 653660http://dx.doi.org/10.1080/13102818.2016.1181989
  53. Idilman R, Baykam N, Kaymakoğlu S, Tabak F, Bahçecioğlu HI, Bektaş A, Bulut C, Günşar F, İnan D, Karaosmanoğlu HK, Karasu Z, Kuşçu F, Mete B, Özbakır Ö, Özdoğan OC, Parlak M, Sırmatel F, Topalak Ö, Ünsal B, Guidelines Study Group VH. Turkey 2017 Clinical Practice Guidelines on recommendations for screening diagnosing and managing hepatitis C virus. Turk J Gastroenterol. 2017 Dec;28(Suppl 2):90-93. doi: 10.5152/tjg.2017.21. PubMed PMID: 29303105.
  54. Demirtaş CÖ, Özdoğan OC. Convenient chronic hepatitis B candidates for antiviral cessation and retreatment after relapse: When and who? Turk J Gastroenterol. 2018 Nov;29(6):720-721. doi: 10.5152/tjg.2018.290918. PubMed PMID: 30381278; PubMed Central PMCID: PMC6284689.
  55. Duman DG, Zibandeh N, Ugurlu MU, Celikel C, Akkoc T, Banzragch M, Genc D,Ozdogan O, Akkoc T. Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model. Mol Biol Rep. 2019 Jun;46(3):2997-3008. doi: 10.1007/s11033-019-04736-4. Epub 2019 Mar 8. PubMed PMID: 30850965.
  56. Keklikkıran Ç, Özdoğan OC. Thermal ablation of mucosal defect margins reduces adenoma recurrence after colonic endoscopic mucosal resection. Turk J Gastroenterol. 2019 Jun;30(6):580-581. doi: 10.5152/tjg.2019.210519. PubMed PMID: 31144663.
  57. Gunes Yegin E, Durusoy SS, Ture Ozdemir F, Kombak EF, Ataizi-Celikel C, Ozdogan OC. Appraising diagnostic performance of ELF test by pathological staging and digital quantification of liver fibrosis..Ann Hepatol. 2019 Nov-Dec;18(6):833-840. doi: 10.1016/j.aohep.2019.06.015.
  58. Kesen O, Kani HT, Yanartaş Ö, Aykut UE, Gök B, Gündüz F, Yılmaz Y, Özdoğan OC, Özen Alahdab Y. Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents. Turk J Gastroenterol. 2019 Sep;30(9):801-806. doi: 10.5152/tjg.2019.18679.
  59. Demirtas CO, Gunduz F, Kani HT, Keklikkiran C, Alahdab YO, Yilmaz Y, Duman DG, Atug O, Giral A, Aslan R, Cagatay NS, Ozkan B, Ozdogan OC External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients. .Eur J Gastroenterol Hepatol. 2020 Jul;32(7):882-888.
  60. Demirtas CO, Gunduz F, Tuney D, Baltacioglu F, Kani HT, Bugdayci O, Alahdab YO, Ozdogan OC Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients.Eur J Gastroenterol Hepatol. 2020 Apr;32(4):517-523. doi: 10.1097/MEG.0000000000001528